Media Articles Related to Tilade (Nedocromil Inhalation)
Spiriva Respimat now available in the U.S. for maintenance treatment of asthma in adults and adolescents
Source: Respiratory / Asthma News From Medical News Today [2016.02.04]
Boehringer Ingelheim has announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S.
Cancer drug helps combat asthma in mice
Source: Respiratory / Asthma News From Medical News Today [2016.02.02]
In a mouse model of allergic asthma, dasatinib - an enzyme inhibitor approved for the treatment of chronic myelogenous leukemia - reduced inflammation, enhanced airway repair, and improved lung...
Asthma-COPD Overlap -- A New Clinical Entity
Source: Medscape Allergy & Clinical Immunology Headlines [2016.02.01]
You know them individually, but what about together? A new review keeps clinicians up-to-date on identification and management of the asthma-COPD overlap syndrome.
Medscape Pulmonary Medicine
Do asthma and COPD truly exist?
Source: Respiratory / Asthma News From Medical News Today [2016.02.01]
Defining a patient's symptoms using the historical diagnostic labels of asthma and chronic obstructive pulmonary disease (COPD) is an outdated approach to understanding an individual's condition...
Asthma and allergies: a protective factor in farm milk
Source: Allergy News From Medical News Today [2016.01.27]
Fresh, unprocessed cow's milk has a higher content of omega-3 fatty acids than does pasteurized, homogenized or low-fat milk.
Published Studies Related to Tilade (Nedocromil Inhalation)
Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents. [2009.05]
OBJECTIVES: To determine whether long-term, continuous use of inhaled anti-inflammatory medications affects asthma outcomes in children with mild to moderate asthma after use is discontinued... CONCLUSIONS: Clinically meaningful improvements in the control of asthma and in airway responsiveness achieved during continuous treatment with inhaled corticosteroids do not persist after continuous treatment is discontinued.
AMP challenge induces a decrease in FE(NO) in asthmatic subjects modulated by nedocromil. [2006.12]
BACKGROUND: Allergen challenge results in an immediate reduction in exhaled nitric oxide (FE(NO)) followed by a long-term increase. To study mast cell activation in relation to nitric oxide (NO), the study investigated the effect of inhaled adenosine monophosphate (AMP) as a mast cell activator and mast cell stabilizer - nedocromil sodium - on FE(NO). The NO synthase (NOS) iso-enzyme involved was studied by the NOS inhibitor aminoguanidine... CONCLUSIONS: The AMP challenge caused a reduction in FE(NO) as a result of prior treatment with nedocromil. Aminoguanidine abolished the nedocromil-induced protection on the late reduction in FE(NO), but not on AMP PC(20). Inducible NOS was implicated in the late FE(NO) decrease after the AMP challenge.
Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. [2006.05]
BACKGROUND: The preventive use of medications has been proposed to be effective in the treatment of seasonal rhinitis. OBJECTIVE: To evaluate the efficacy and safety of mometasone furoate and nedocromil sodium nasal sprays as prophylactic treatment for moderate to severe seasonal allergic rhinitis (SAR). PATIENTS: Sixty-one patients were recruited from 3 referral allergy centers. Inclusion criteria were history of SAR for 2 years or longer, sensitization to relevant local pollen (grasses, Parietaria, and olive), and age older than 12 years... CONCLUSIONS: Prophylactic administration of mometasone furoate before the pollen season is safe and may lead to improved control of SAR compared with the use of nedocromil sodium.
Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects. [2005.09]
CONCLUSIONS: Nedocromil strongly attenuates mannitol-induced bronchoconstriction but has a negligible effect on mannitol-provoked cough. Therefore, these responses seem to have different pathways in asthma. Recording of both provoked coughs and induced bronchoconstriction during mannitol challenge may provide supplementary information about a patient's disease.
Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: A randomized pragmatic study. [2004.08]
Asthma severity can be judged by measurements of symptoms, lung function, and medication requirements. The objective was to compare the effect of a 4-wk monotherapy with low-dose triamcinolone, montelukast and nedocromil on asthma control, lung function, eosinophil blood count, and bronchial hyper-reactivity in children with mild to moderate asthma allergic to dust mite...
Clinical Trials Related to Tilade (Nedocromil Inhalation)
Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) [Completed]
The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy
compared to bronchodilator therapy on the course of asthma, particularly on lung function
and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
Immune Dysregulation in Children and Adults With Asthma [Completed]
To immunize both normal and asthmatic subjects with a neoantigen, keyhole limpet hemocyanin
(KLH) and observe the type of antibody and T cell response that develops.
Comparing Modified Meek and Mesh Techniques [Completed]
This is a clinical trial study that compare two plastic surgery techniques in patients with
third degree of burning and both techniques are used in all patients but in different areas
of burning sites of the patients.
Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232) [Completed]
Patients were treated with either montelukast 4 mg oral granules or usual care. Patients who
completed Protocol MK0476-176-01 (NCT00943683) had the option to enroll in this study.
Additionally, patients with asthma who were 6 to 11 months of age and who had not
participated in Protocol MK0476-176-01, could also enroll.